Charcot-Marie-Tooth Disease Pipeline Analysis Report 2026

Report Coverage

The Charcot-Marie-Tooth Disease Pipeline Analysis Report by Expert Market Research gives comprehensive insights into Charcot-Marie-Tooth disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Charcot-Marie-Tooth disease. The Charcot-Marie-Tooth disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Charcot-Marie-Tooth disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Charcot-Marie-Tooth disease treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Charcot-Marie-Tooth disease.

Read more about this report - Request a Free Sample

Charcot-Marie-Tooth Disease Pipeline Outlook

The Charcot-Marie-tooth disease pipeline is advancing through innovative gene therapies, stem cell therapies, and neuromuscular modulators aimed at addressing the underlying causes of inherited peripheral neuropathies. Promising candidates such as EN001, scAAV1.tMCK.NTF3, and NMD670 (ignaseclant) are expanding the therapeutic landscape. In March 2025, the U.S. FDA granted Orphan Drug Designation to EN001, ENCell's investigational mesenchymal stem cell therapy, following encouraging Phase I safety results. This regulatory milestone is expected to accelerate clinical development and highlights growing momentum toward disease-modifying treatments for Charcot-Marie-tooth disease.

Charcot-Marie-Tooth Disease Epidemiology

Charcot-Marie-Tooth (CMT) disease is among the most common inherited peripheral neuropathies, with an estimated prevalence of 1 in 2,500 people worldwide, affecting approximately 2.8 million individuals globally. CMT1A, caused by PMP22 gene duplication, accounts for nearly 50% of all CMT cases. The disease affects males and females equally and typically presents during childhood or early adulthood, although age of onset varies by subtype. Improved genetic testing has increased diagnosis rates and enhanced epidemiological characterization across diverse populations.

Charcot-Marie-Tooth Disease – Pipeline Therapeutic Assessment

Charcot-Marie-Tooth Disease Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total Charcot-Marie-Tooth disease clinical trials. Early Phase I (0.00%), Phase I (26.67%), Phase II (40.00%), Phase III (20.00%), and Phase IV (13.33%), reflecting the continued advancement of therapeutic candidates through the clinical development pipeline.

Charcot-Marie-Tooth Disease Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the Charcot-Marie-Tooth disease pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The Charcot-Marie-Tooth disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Charcot-Marie-Tooth disease. In January 2025, the U.S. FDA granted Orphan Drug Designation to NMD670 (ignaseclant), an oral skeletal muscle-specific ClC-1 inhibitor developed by NMD Pharma A/S, for the treatment of Charcot-Marie-Tooth disease.

Charcot-Marie-Tooth Disease Clinical Trials – Key Players

The EMR report for the Charcot-Marie-Tooth disease pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed Charcot-Marie-Tooth disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Charcot-Marie-Tooth disease clinical trials:

• Elpida Therapeutics SPC
• ENCell
• Novartis Pharmaceuticals
• Biogen
• NMD Pharma A/S
• DTx Pharma, Inc.
• Atsena Therapeutics
• Regenxbio Inc.
• uniQure N.V.
• Solid Biosciences
• PepGen Inc.
• Wave Life Sciences Ltd.

Charcot-Marie-Tooth Disease – Emerging Drugs Profile

Key Questions Answered in the Charcot-Marie-Tooth Disease Pipeline Insight Report

• Which companies/institutions are leading the Charcot-Marie-Tooth disease drug development?
• Which company is leading the Charcot-Marie-Tooth disease pipeline development activities?
• What is the current Charcot-Marie-Tooth disease commercial assessment?
• What are the opportunities and challenges present in the Charcot-Marie-Tooth disease pipeline landscape?
• What is the efficacy and safety profile of Charcot-Marie-Tooth disease pipeline drugs?
• Which company is conducting major trials for Charcot-Marie-Tooth disease drugs?
• Which companies/institutions are involved in Charcot-Marie-Tooth disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in Charcot-Marie-Tooth disease?

Reasons To Buy This Report

The Charcot-Marie-Tooth Disease Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for Charcot-Marie-Tooth disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Charcot-Marie-Tooth disease collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Dental Crowns and Bridges Market

Dental Hygiene Devices Market

Dental Laboratories Market

Dental Lasers Market